Compare Alcon AG (ALC) vs Halliburton Company (HAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Halliburton Company — how do they compare? Alcon AG trades at $66.71 (market cap $32.69B), while Halliburton Company trades at $34.82 (market cap $28.23B). The key difference: Alcon AG is the larger of the two by market cap, and Halliburton Company pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| ALC | HAL | |
|---|---|---|
Market Cap | $32.69B | $28.23B |
Sector | Health | Energy |
52-Week High | $92.22 | $42.98 |
52-Week Low | $62.02 | $20.50 |
Enterprise Value | $36.28B | $34.31B |
Dividend Yield | 0.54% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Halliburton (HAL) trades at $33.79, up 2.52% today, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 18.23 and ROE of 14.56%, though 2025 revenue declined to $22.18B. Recent news highlights digital transformation partnerships and upcoming Q2 2026 earnings, while analyst consensus remains strongly bullish with a $44.22 price target.
HAL presents a compelling value opportunity with 30% upside to consensus target, supported by consistent earnings outperformance and strategic digital initiatives. Key risks include oil price volatility and competitive pressures in energy services. The stock's current discount to analyst targets and strong institutional support suggest potential for recovery despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
